TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Brief Summary: The purpose of this study is to compare the effectivity and safety of atrial fibrillation ablation, in comparison to antiarrhythmic drug therapy in patients with refractory, persistent atrial fibrillation.


Options:
A: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
B: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ranolazine placebo, Drug: Dronedarone placebo | Arm Label: Ranolazine 750 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Dronedarone placebo | Arm Label: Dronedarone 225 mg; Type: EXPERIMENTAL; Interventions: Drug: Dronedarone, Drug: Ranolazine placebo | Arm Label: Ranolazine 750 mg + Dronedarone 225 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Dronedarone | Arm Label: Ranolazine 750 mg + Dronedarone 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranolazine, Drug: Dronedarone | Intervention Type: DRUG; Name: Ranolazine; Assigned to Arm(s): Ranolazine 750 mg, Ranolazine 750 mg + Dronedarone 150 mg, Ranolazine 750 mg + Dronedarone 225 mg | Intervention Type: DRUG; Name: Dronedarone; Assigned to Arm(s): Dronedarone 225 mg, Ranolazine 750 mg + Dronedarone 150 mg, Ranolazine 750 mg + Dronedarone 225 mg | Intervention Type: DRUG; Name: Ranolazine placebo; Assigned to Arm(s): Dronedarone 225 mg, Placebo | Intervention Type: DRUG; Name: Dronedarone placebo; Assigned to Arm(s): Placebo, Ranolazine 750 mg
D: Arm Label: No Amiodarone; Type: ACTIVE_COMPARATOR; Interventions: Other: No Amiodarone | Arm Label: Amiodarone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: No Amiodarone; Assigned to Arm(s): No Amiodarone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation
Brief Summary: The purpose of this study is to compare the effectivity and safety of atrial fibrillation ablation, in comparison to antiarrhythmic drug therapy in patients with refractory, persistent atrial fibrillation.


Options:
A: Intervention Type: PROCEDURE; Name: Circumferential Pulmonary Vein Ablation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Antiarrhythmic Drug Therapy; Assigned to Arm(s): N/A
B: Arm Label: Dronedarone 400mg bid; Type: EXPERIMENTAL; Interventions: Drug: dronedarone (SR33589) | Arm Label: Amiodarone 600mg/200mg od; Type: ACTIVE_COMPARATOR; Interventions: Drug: amiodarone | Intervention Type: DRUG; Name: dronedarone (SR33589); Assigned to Arm(s): Dronedarone 400mg bid | Intervention Type: DRUG; Name: amiodarone; Assigned to Arm(s): Amiodarone 600mg/200mg od
C: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
D: Intervention Type: DRUG; Name: CELIVARONE (SSR149744C); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Health and Cost Consequenses of Surgical Versus Conservative Treatment for a Comminuted Humerus Fracture. Do Interlocking Plate Surgery Benefit Displaced Proximal Humerus Fractures? A Randomized Clinical Trial
Brief Summary: 1. Do a standardized surgical treatment of unstable displaced proximal humerus fracture in patients aged over 60 compared to a standardized conservative treatment gain a better functional outcome after one year?
2. Do surgical treatment gain more QALY than conservative treatment after one year?


Options:
A: Arm Label: Angular stable plate Philos; Type: ACTIVE_COMPARATOR; Interventions: Device: Reverse total shoulder arthroplasty | Arm Label: Reverse Total Shoulder Artroplasty; Type: EXPERIMENTAL; Interventions: Device: Reverse total shoulder arthroplasty | Intervention Type: DEVICE; Name: Reverse total shoulder arthroplasty; Assigned to Arm(s): Angular stable plate Philos, Reverse Total Shoulder Artroplasty
B: Arm Label: nonoperative management; Type: PLACEBO_COMPARATOR; Interventions: Other: Non operative | Arm Label: locking plate surgical fixation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: locking plate surgical fixation | Intervention Type: OTHER; Name: Non operative; Assigned to Arm(s): nonoperative management | Intervention Type: PROCEDURE; Name: locking plate surgical fixation; Assigned to Arm(s): locking plate surgical fixation
C: Arm Label: PhilosTM with augmentation (Depuy-Synthes); Type: OTHER; Interventions: Device: MultiLoc®-Nail (Depuy-Synthes) | Arm Label: MultiLoc®-Nail (Depuy-Synthes); Type: OTHER; Interventions: Device: PhilosTM with augmentation (Depuy-Synthes) | Intervention Type: DEVICE; Name: PhilosTM with augmentation (Depuy-Synthes); Assigned to Arm(s): MultiLoc®-Nail (Depuy-Synthes) | Intervention Type: DEVICE; Name: MultiLoc®-Nail (Depuy-Synthes); Assigned to Arm(s): PhilosTM with augmentation (Depuy-Synthes)
D: Arm Label: Conservative /Physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Surgery with LCP T plate; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical treatment with LCP | Intervention Type: PROCEDURE; Name: Surgical treatment with LCP; Assigned to Arm(s): Surgery with LCP T plate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Administered High Frequency Chest Wall Oscillation Technique for Mucus Clearance in COPD: An Exploratory Pilot Project Using the SMARTVEST Device
Brief Summary: Patients with Chronic obstructive pulmonary disease (COPD) tend to have cough, excess mucus production and breathlessness as cardinal features. The excess mucus production often leads to frequent infections, exacerbations and poor quality of life. Mucociliary clearance may have an impact on improving symptoms, exercise tolerance, quality of life and reduce exacerbations.

High frequency chest wall oscillation(HFCWO) devices use percussion to the chest wall delivered from a pump through a close fitting inflatable vest. This technique has been shown to enhance mucus clearance in patients with cystic fibrosis and Bronchiectasis. This pilot study was designed to explore the feasibility, tolerance and effectiveness of the HFCWO in patients with advanced COPD.


Options:
A: Arm Label: HFCWO; Type: EXPERIMENTAL; Interventions: Device: HFCWO - SmartVest | Arm Label: Placebo/Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: HFCWO - SmartVest; Assigned to Arm(s): HFCWO
B: Arm Label: Autogenic drainage; Type: ACTIVE_COMPARATOR; Interventions: Other: Autogenic drainage | Arm Label: Slow expiration with glottis opened in lateral posture; Type: ACTIVE_COMPARATOR; Interventions: Other: Slow expiration with glottis opened in lateral posture | Arm Label: Temporary-Positive Expiratory Pressure; Type: ACTIVE_COMPARATOR; Interventions: Other: Temporary-positive expiratory pressure | Intervention Type: OTHER; Name: Autogenic drainage; Assigned to Arm(s): Autogenic drainage | Intervention Type: OTHER; Name: Slow expiration with glottis opened in lateral posture; Assigned to Arm(s): Slow expiration with glottis opened in lateral posture | Intervention Type: OTHER; Name: Temporary-positive expiratory pressure; Assigned to Arm(s): Temporary-Positive Expiratory Pressure
C: Arm Label: Chest Physiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: Chest Physiotherapy + Exercise Program; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy + Exercise Program | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest Physiotherapy + Exercise Program; Assigned to Arm(s): Chest Physiotherapy + Exercise Program
D: Arm Label: Acapella Physiotherapy; Type: EXPERIMENTAL; Interventions: Device: Acapella Physiotherapy | Arm Label: No physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Acapella Physiotherapy; Assigned to Arm(s): Acapella Physiotherapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Extension, Multicentre, Multi-national Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg,1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)
Brief Summary: Patients who have completed the 12 weeks treatment of the PATENT-1 trial (study number 12934) will be asked to participate in this long term extension study with BAY63-2521.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Arm 1
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 1
C: Arm Label: Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (Adempas, BAY63-2521), Drug: Sildenafil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Sildenafil | Intervention Type: DRUG; Name: Riociguat (Adempas, BAY63-2521); Assigned to Arm(s): Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sildenafil; Assigned to Arm(s): Placebo, Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Riociguat (BAY63-2521) | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Riociguat (BAY63-2521); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Acute Severe Alcoholic Hepatitis With Corticoids Plus N Acetyl Cysteine Versus Corticoids Alone: a French Multicentre Randomized Controlled Study.
Brief Summary: 35% of Acute Alcoholic Hepatitis patients (AAH) do not respond to corticoids and died after 6 months. Chronic alcohol abuse depletes glutathione in the hepatocytes and makes the latter more sensitive to excessive TNFα levels. Re-establishment of a stock of antioxidants by administration of a precursor (N-acetyl cysteine, NAC) in combination with corticoids (C) could make the hepatocytes more resistant and improve survival. The investigators' study's primary endpoint was improvement of survival at 6 months. The secondary endpoints were survival at 1 and 3 months, tolerance of NAC and a drop in blood bilirubin levels at D7


Options:
A: Arm Label: Corticoids plus N Acetyl Cysteine; Type: EXPERIMENTAL; Interventions: Drug: Corticoids plus N Acetyl Cysteine | Intervention Type: DRUG; Name: Corticoids plus N Acetyl Cysteine; Assigned to Arm(s): Corticoids plus N Acetyl Cysteine
B: Arm Label: Pentoxifylline + Prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Arm Label: Placebo + Prednisolone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pentoxifylline | Intervention Type: DRUG; Name: Pentoxifylline; Assigned to Arm(s): Placebo + Prednisolone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Pentoxifylline + Prednisolone
C: Arm Label: Prednisone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pentoxifylline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Prednisone plus metadoxine; Type: EXPERIMENTAL; Interventions: Drug: Prednisone plus Metadoxine | Arm Label: Pentoxifylline plus metadoxine; Type: EXPERIMENTAL; Interventions: Drug: Pentoxifylline plus Metadoxine | Intervention Type: DRUG; Name: Prednisone plus Metadoxine; Assigned to Arm(s): Prednisone plus metadoxine | Intervention Type: DRUG; Name: Pentoxifylline plus Metadoxine; Assigned to Arm(s): Pentoxifylline plus metadoxine
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: pentoxifylline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: pentoxifylline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder
Brief Summary: The primary purpose of this study is to compare the antidepressant efficacy and safety of two doses of desvenlafaxine succinate sustained release (10 and 50 mg/day) in adults with Major Depressive Disorder. The study will also assess changes in sexual function and general and functional quality of life outcomes.


Options:
A: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
B: Arm Label: Desvenlafaxine succinate sustained release 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release 10mg | Arm Label: Desvenlafaxine succinate sustained release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release 50 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release 10mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 10 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release 50 mg; Assigned to Arm(s): Desvenlafaxine succinate sustained release 50 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712, Drug: ADT | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: ADT | Intervention Type: DRUG; Name: OPC-34712; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: ADT; Assigned to Arm(s): 1, 2
D: Arm Label: deprexis®; Type: EXPERIMENTAL; Interventions: Other: deprexis® | Arm Label: Information; Type: PLACEBO_COMPARATOR; Interventions: Other: Information | Intervention Type: OTHER; Name: deprexis®; Assigned to Arm(s): deprexis® | Intervention Type: OTHER; Name: Information; Assigned to Arm(s): Information

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Flexible-dose Trial Evaluating the Efficacy and Safety of 12 Weeks of Treatment With Sertindole or Olanzapine in Patients With Schizophrenia in Asia
Brief Summary: The purpose of this study is to assess the efficacy and safety of sertindole in patients with schizophrenia in Asia.


Options:
A: Arm Label: 600 mg/day quetiapine (Group B); Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Arm Label: 1200 mg/day quetiapine (Group A); Type: EXPERIMENTAL; Interventions: Drug: quetiapine | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 1200 mg/day quetiapine (Group A) | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 600 mg/day quetiapine (Group B)
B: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A
C: Arm Label: Sertindole; Type: EXPERIMENTAL; Interventions: Drug: Sertindole | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine | Intervention Type: DRUG; Name: Sertindole; Assigned to Arm(s): Sertindole | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prize Reinforcement for Smoking Cessation
Brief Summary: Nicotine dependence is prevalent in society, cigarette smoking is associated with several known health risks, and most dependent individuals find it very difficult to stop smoking cigarettes. The present study will test the efficacy of a behavioral smoking cessation treatment, prize-based contingency management, that has not undergone rigorous study with respect to smoking, it but has demonstrated efficacy in reducing use of other substances (e.g. cocaine). If efficacious, prize-based contingency management would add to our repertoire of efficacious smoking cessation treatments.


Options:
A: Arm Label: CBT-AD; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-AD | Arm Label: ETAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ETAU | Intervention Type: BEHAVIORAL; Name: CBT-AD; Assigned to Arm(s): CBT-AD | Intervention Type: BEHAVIORAL; Name: ETAU; Assigned to Arm(s): ETAU
B: Arm Label: Traditional Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Traditional Contingency Management | Arm Label: Early Enhanced Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Early Enhanced Contingency Management | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Treatment | Intervention Type: BEHAVIORAL; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BEHAVIORAL; Name: Traditional Contingency Management; Assigned to Arm(s): Traditional Contingency Management | Intervention Type: BEHAVIORAL; Name: Early Enhanced Contingency Management; Assigned to Arm(s): Early Enhanced Contingency Management
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Arm Label: physical activity program; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise and counseling (for smoking cessation and physical activity) | Intervention Type: BEHAVIORAL; Name: Exercise and counseling (for smoking cessation and physical activity); Assigned to Arm(s): Control, physical activity program
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Twelve Step Facilitation | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Cognitive Behavioral Treatment | Intervention Type: BEHAVIORAL; Name: Twelve Step Facilitation; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Integrated Cognitive Behavioral Treatment; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prize Reinforcement for Smoking Cessation
Brief Summary: Nicotine dependence is prevalent in society, cigarette smoking is associated with several known health risks, and most dependent individuals find it very difficult to stop smoking cigarettes. The present study will test the efficacy of a behavioral smoking cessation treatment, prize-based contingency management, that has not undergone rigorous study with respect to smoking, it but has demonstrated efficacy in reducing use of other substances (e.g. cocaine). If efficacious, prize-based contingency management would add to our repertoire of efficacious smoking cessation treatments.


Options:
A: Arm Label: Traditional Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Traditional Contingency Management | Arm Label: Early Enhanced Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Early Enhanced Contingency Management | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Treatment | Intervention Type: BEHAVIORAL; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BEHAVIORAL; Name: Traditional Contingency Management; Assigned to Arm(s): Traditional Contingency Management | Intervention Type: BEHAVIORAL; Name: Early Enhanced Contingency Management; Assigned to Arm(s): Early Enhanced Contingency Management
B: Arm Label: tobacco abstinent contingent voucher; Type: EXPERIMENTAL; Interventions: Behavioral: tobacco abstinent contingent | Arm Label: non-contingent; Type: EXPERIMENTAL; Interventions: Behavioral: non-contingent | Arm Label: no voucher; Type: OTHER; Interventions: Behavioral: control | Intervention Type: BEHAVIORAL; Name: tobacco abstinent contingent; Assigned to Arm(s): tobacco abstinent contingent voucher | Intervention Type: BEHAVIORAL; Name: non-contingent; Assigned to Arm(s): non-contingent | Intervention Type: BEHAVIORAL; Name: control; Assigned to Arm(s): no voucher
C: Arm Label: Original contingent vouchers schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Voucher-based incentives | Arm Label: Revised contingent vouchers schedule; Type: EXPERIMENTAL; Interventions: Behavioral: Voucher-based incentives | Arm Label: Non-contingent vouchers schedule; Type: SHAM_COMPARATOR; Interventions: Behavioral: Voucher-based incentives | Intervention Type: BEHAVIORAL; Name: Voucher-based incentives; Assigned to Arm(s): Non-contingent vouchers schedule, Original contingent vouchers schedule, Revised contingent vouchers schedule
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: Enhanced Traditional Care control; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Traditional Care control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Enhanced Traditional Care control; Assigned to Arm(s): Enhanced Traditional Care control

Answer: A